Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.51 |
| ▸ | LAP3 | P28838 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13585300 | 1.00 | NOD1 (0.58) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| SCHEMBL234160 | 1.00 | NOD1 (0.58) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| SCHEMBL13585297 | 1.00 | NOD1 (0.58) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| SCHEMBL234161 | 1.00 | NOD1 (0.58) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| Glutamic Acid SCHEMBL4393021 | 0.95 | FOLH1 (0.60) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| D-Glutamate SCHEMBL4393018 | 0.95 | FOLH1 (0.60) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| Glutamine SCHEMBL4395724 | 0.94 | KMT2A (0.56) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| Glutamine SCHEMBL4395718 | 0.94 | KMT2A (0.56) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| Aspartic Acid SCHEMBL4390861 | 0.93 | NOD1 (0.52) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| Aspartic Acid SCHEMBL4390865 | 0.93 | NOD1 (0.52) | NOD1ALDH1A1FOLH1PTGS1GSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114373510-B | Metabolic marker for diagnosing or monitoring lung cancer and screening method and application thereof | 武汉迈特维尔医学科技有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-114373510-A | Metabolic marker for lung cancer diagnosis or monitoring and screening method and application thereof | 武汉迈特维尔生物科技有限公司 | 2022-04-19 | — | — | CN | claimed |
| US-5126245-A | REAGENTS FOR ASSAY OF GAMMA-GLUTAMYLTRANSPEPTIDASE | UNITIKA LTD. (JP) | 1992-06-30 | — | — | US | claimed |
| EP-0266905-A1 | Reagents for assay of gamma-glutamyl-transpeptidase | UNITIKA LTD. (JP) | 1988-05-11 | — | — | EP | claimed |
| JP-63094998-A | — | — | None | — | — | JP | disclosed |
| CN-114373510-B | Metabolic marker for diagnosing or monitoring lung cancer and screening method and application thereof | 武汉迈特维尔医学科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-114373510-A | Metabolic marker for lung cancer diagnosis or monitoring and screening method and application thereof | 武汉迈特维尔生物科技有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-5126245-A | REAGENTS FOR ASSAY OF GAMMA-GLUTAMYLTRANSPEPTIDASE | UNITIKA LTD. (JP) | 1992-06-30 | — | — | US | disclosed |
| EP-0266905-B1 | REAGENTS FOR ASSAY OF GAMMA-GLUTAMYL-TRANSPEPTIDASE | UNITIKA LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0266905-A1 | Reagents for assay of gamma-glutamyl-transpeptidase | UNITIKA LTD. (JP) | 1988-05-11 | — | — | EP | disclosed |
| JP-S6394998-A | REAGENT FOR DETERMINING GAMMA-GLUTAMYL TRANSPEPTIDASE | UNITIKA LTD | 1988-04-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | NOD1 1020/4885ALDH1A1 3484/4885FOLH1 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.